Compare · COAG vs PFE
COAG vs PFE
Side-by-side comparison of Hemab Therapeutics Holdings Inc. (COAG) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. COAG focuses on Biotechnology: Biological Products (No Diagnostic Substances), while PFE focuses on Biotechnology: Pharmaceutical Preparations.
- PFE is the larger of the two at $156.18B, about 85.1x COAG ($1.84B).
- PFE has been more active in the news (17 items in the past 4 weeks vs 8 for COAG).
- PFE has more recent analyst coverage (25 ratings vs 0 for COAG).
- Company
- Hemab Therapeutics Holdings Inc.
- Pfizer Inc.
- Price
- -
- -
- Market cap
- $1.84B
- $156.18B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 8
- 17
- Recent ratings
- 0
- 25
Hemab Therapeutics Holdings Inc.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab's mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an antifibrinolytic targeting plasmin inhibition in clinical development for heavy menstrual bleeding.
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest COAG
- Hemab Therapeutics to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by Hemab Therapeutics Holdings Inc.
- Hemab Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia
- Amendment: SEC Form SCHEDULE 13G/A filed by Hemab Therapeutics Holdings Inc.
- Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
- Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026
Latest PFE
- Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases
- Chairman & CEO Bourla Albert was granted 21 units of Phantom Stock Units SSP (SEC Form 4)
- FDA Approval for DEFEROXAMINE MESYLATE issued to HOSPIRA
- SEC Form 13F-HR filed by Pfizer Inc.
- Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- FDA Approval for HYMPAVZI issued to PFIZER INC
- Pfizer downgraded by DZ Bank
- Pfizer Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Election Day Trading Splits the Benchmarks, With the Dow Lower and the Nasdaq Higher